Pioneering a New Era of Detection and Diagnosis to Enhance Health Span
It starts with a breath… Trace Sensing Technologies’ patented thermodynamic sensor system, TRACE-E™, detects biomarkers from non-invasive mediums.
Our Commitments
Leave a lasting impact on the lives of patients and their families by empowering better decisions based on early insights into diseases that can help lengthen one’s health span.
Bring first-in-class sensor technology to healthcare and create products that revolutionize the diagnostic experience for patients and providers.
Trace Sensing researchers, engineers, and product builders share a passion and commitment to translate science into real world solutions that change lives.
Our first product under development, TRACE-E™, is a medical device built around Trace Sensing’s thermodynamic sensor technology.
Contact us for a demo and technology review.
Latest News
-
FDA Q-Submission Meeting Completed – December 20, 2023
Meeting with FDA reviewers led to a productive and insightful discussion on the implementation of TRACE-E in clinical settings, the use and validation of breath biomarkers, data requirements and testing protocols.
Data Requirements & Testing Feedback
•Types of data needed for when considering TRACE-E for market approval including both analytical and clinical data.
• FDA reviewers acknowledged the uniqueness of TRACE-E as a real-time diagnostic device
Future Plans and Outcomes
• Our teams have begun incorporating feedback into 2024 planning including the implementation strategy, clinical outreach, testing protocols, and more.
• Anticipate meeting with the review team again in Q4 2024 to discuss our progress throughout the year and next steps.
-
Trace Sensing has been accepted into the New England Medical Innovation Center (NEMIC) DLT Accelerator Program
NEMIC is an incredible organization centered around the advancement of innovators in the medical technology space.
Their dedication to transform healthcare and enhance quality of life perfectly aligns with our commitments and we are excited to collaborate with them.
As part of the program, they will be supporting us in several areas pivotal to our development including market studies, regulatory analysis, and much more.
-
Completed User Testing – California (US) & Rhode Island (US)
We completed device testing at a clinic in California and a health expo in Rhode Island totaling 108 patients –across several disease categories.
Early results are promising and will help to pave the way for informed and intentional user experience (UX)/patient experience designs and user interface (UI) considerations.
We are now testing and evaluating different form factors as we near completion of the latest iteration of the TRACE-E device.
-
Close of Our Seed Round (2023)
We are excited to welcome several new supporters to Trace Sensing Technologies as we announce the closure of our seed round.
Thank you for your continued support, Nicholas and Van Budano, Peggy Carter, Bill Day, Saucon Creek Senior Living L.P. and their President James Kusko.
Their support will undoubtedly help us achieve our goal of revolutionizing early disease diagnosis in pursuit of a better experience for patients.
They are extremely supportive of Trace Sensing’s mission and vision and strongly believe in the positive impact our team will have on the healthcare industry.
Advancing the Science
of Detection, Diagnosis, & Discovery
The Team
Trace Sensing researchers, engineers, and product builders have a combined track record of decades of experience commercializing intellectual property into practical solutions for real world applications.
Next Generation Research
Trace Sensing Technologies’ founders include chemical engineers Peter Ricci, PhD and Otto Gregory, PhD.
Initial sensor capabilities developed for the defense industry attracted $3M in funding from Homeland Security, DoD, and the Army.
Federal funding resulted in 15 years of sensor R&D at the University of Rhode Island.
Engineering & Product Design
SMD - Strain Measurement Devices, a manufacturer of sensors for medical devices and other high precision applications, is a strategic and equity partner.
ISO 13485 certified manufacturing facility.
Highly skilled engineering staff with decades of production and manufacturing experience.
US & UK based facilities with state-of-the-art equipment and tooling.
-
Peter Ricci III
PRESIDENT & CEO
-
Dr. Otto Gregory
CHAIRMAN
-
Otto Gregory IV
VP, CONTROLLER, & TREASURER
-
Fred Jackson
COO & SECRETARY
-
Danny Shapiro
VP & DIRECTOR OF ENGINEERING
-
Courtney Gyrath
HEAD OF STRATEGY
-
Ksenia Boyer
PRINCIPAL PRODUCT MANAGER
-
Daniel Sterling
PRINCIPAL DESIGNER
-
Neal Wostbrock
MECHANICAL ENGINEER
-
Eddie Krutyanskiy
MECHANICAL ENGINEER
-
Cobey Smith
ELECTRICAL ENGINEER
The Promise of Making a Difference
Achievements & Collaborations
Vision to Reality
PUBLICATIONS & PATENTS
-
Sensors for the detection of ammonia as a potential biomarker for health screening
We demonstrate the selective detection of ammonia using a vapor phase thermodynamic sensing platform capable of being employed as part of a health screening protocol. The results show that our detection system has the remarkable ability to selectively detect trace levels of ammonia in the vapor…
-
Free‐standing, thin‐film sensors for the trace detection of explosives
We develop a thermodynamic sensor that can detect a multitude of explosives in the vapor phase at the part-per-trillion (ppt) level. Improved sensor response and selectivity are achieved by fabricating free-standing, ultrathin film (1 µm thick) microheater sensors for this purpose. The fabrication method used here relies on…
-
Continuous Monitoring of TATP Using Ultrasensitive, Low-Power Sensors
We develop a thermodynamic sensor that can detect TATP and nitrogen-based explosives in the vapor phase at the part-per-billion (ppb) level. These ultrathin sensors show unparalleled sensitivity and could even be operated at low enough powers to enable deployment on drones. Enhanced sensitivity and selectivity…
-
Orthogonal Sensors for the Trace Detection of Explosives
We demonstrate a thermodynamic sensor platform employing thin film microheaters and metal oxide catalysts that can detect TATP and 2,4-DNT at the part-per-billion (ppb) level. We add a conductometric sensor platform to this thermodynamic platform to form an orthogonal sensor capable of interrogating the same catalyst…
-
Trace Detection of Explosives Using Metal Oxide Catalysts
We explore specific oxidation-reduction reactions on the surface of metal oxide catalysts (SnO, Cu2O, ZnO) to determine the sensing mechanism of our thermodynamic sensors. These surface reactions are specific to the explosive molecule of interest, catalyst, and the oxidation states of the catalyst…
-
Eight (8) Patents Issued
Four (4) patents issued and 4 pending applications/continuations for foundational, ultra-sensitive sensor technology consisting of a microheater coated in a catalyst to detect molecules and compounds in the vapor phase.
ACHIEVEMENTS
Unique CKD, DM II, and Cancer patients in clinical and academic settings, as well as with a handful of healthy controls, with positive signals.
Investigated use of core sensor technology for potential applications in healthcare for clinical diagnostics, disease progression, and therapeutic efficacy.
Began exploring blood glucose monitoring in Type II diabetes patients vs. typical BGM/CGM devices in 2020. Results demonstrated 96% correlation.
Runner-up in the 2023 Rhode Island Business Competition.
Developed and submitted a pre-submission request for market authorization with the FDA; Request accepted, first meeting anticipated Q4 2023.
COLLABORATIONS
Novo Nordisk Partnership
Entered into innovation partnership with Novo Nordisk in June 2021 to explore potential as diagnostic/monitoring device for cardio metabolic disease (CMD).
Independently validated business entity, clinical, and patient use cases.
Use cases available by request, with results for: earliest possible disease detection/diagnosis.
Progression/treatment efficacy monitoring at point-of-care across several therapeutic categories - enabling earlier intervention, more effective treatment, improved patient outcomes, and lower overall costs.
Journal for Thoracic and Cardiovascular Surgery
Mentioned by researchers from Memorial Sloan Kettering Cancer Center in the Journal for Thoracic and Cardiovascular Surgery as a “next generation” sensor technology with the ability to facilitate real-time readouts of the exhalates which acts as a “differentiator” that will allow “increased clinical implementation.”
Expanded Lab & Patient Testing
Initial confirmatory lab and patient testing expanded to include biomarkers for: cardiovascular disease, Alzheimers’ disease, NASH; various reproductive, respiratory, genitourinary, and other metabolic cancers.
What Others are Saying
-
"I would 1000% want to use this instead."
Laurie P.
Metastatic Ovarian Cancer Patient -
"I would pay for this solution. I don't have any information [getting sicker and doesn't know why]."
Jamie K.
Diabetes Patient -
"I would purchase one of these devices the moment it was available."
Lindsey B.
Endocrinologist -
"Do patients know that all diagnoses without lab confirmation and many with lab confirmation are just hypthoses?"
Keith F.
Healthcare Provider -
"My doctors had a hard time [with diagnosis], even with good tools. This could help people."
James B.
Testicular Cancer Patient